JOP20200330A1 - مركبات حمض أميني بروابط غير متفرعة وطرق استخدامها - Google Patents
مركبات حمض أميني بروابط غير متفرعة وطرق استخدامهاInfo
- Publication number
- JOP20200330A1 JOP20200330A1 JOP/2020/0330A JOP20200330A JOP20200330A1 JO P20200330 A1 JOP20200330 A1 JO P20200330A1 JO P20200330 A JOP20200330 A JO P20200330A JO P20200330 A1 JOP20200330 A1 JO P20200330A1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- amino acid
- acid compounds
- unbranched
- linkers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690939P | 2018-06-27 | 2018-06-27 | |
| PCT/US2019/039624 WO2020006315A1 (en) | 2018-06-27 | 2019-06-27 | Amino acid compounds with unbranched linkers and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20200330A1 true JOP20200330A1 (ar) | 2020-12-20 |
Family
ID=68987528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2020/0330A JOP20200330A1 (ar) | 2018-06-27 | 2019-06-27 | مركبات حمض أميني بروابط غير متفرعة وطرق استخدامها |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11396506B2 (enExample) |
| EP (1) | EP3813818A4 (enExample) |
| JP (2) | JP7425757B2 (enExample) |
| KR (1) | KR20210043561A (enExample) |
| CN (1) | CN112689507B (enExample) |
| AU (1) | AU2019295769B2 (enExample) |
| BR (1) | BR112020026278A2 (enExample) |
| CA (1) | CA3104682A1 (enExample) |
| CL (1) | CL2020003382A1 (enExample) |
| CR (1) | CR20210041A (enExample) |
| CU (1) | CU24693B1 (enExample) |
| DO (1) | DOP2020000255A (enExample) |
| EA (1) | EA202190134A1 (enExample) |
| EC (1) | ECSP21005655A (enExample) |
| IL (2) | IL279717B2 (enExample) |
| JO (1) | JOP20200330A1 (enExample) |
| MX (1) | MX2020014086A (enExample) |
| PE (1) | PE20210137A1 (enExample) |
| PH (1) | PH12020552260A1 (enExample) |
| SA (1) | SA520420897B1 (enExample) |
| SG (1) | SG11202013027RA (enExample) |
| TW (1) | TWI841573B (enExample) |
| WO (1) | WO2020006315A1 (enExample) |
| ZA (1) | ZA202100211B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| CA3045491A1 (en) | 2016-12-29 | 2018-07-19 | Indalo Therapeutics, Inc. | Integrin antagonists |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| CN112654621B (zh) | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| TWI776067B (zh) | 2018-06-29 | 2022-09-01 | 美商維托平面玻璃有限責任公司 | 可燒除保護性塗層 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| PT3844162T (pt) | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| EP4076454A1 (en) * | 2019-12-20 | 2022-10-26 | Novartis AG | Combination treatment of liver diseases using integrin inhibitors |
| IL293895A (en) * | 2019-12-20 | 2022-08-01 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| GB202010626D0 (en) * | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| TW202235417A (zh) | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| GB202209228D0 (en) | 2022-06-23 | 2022-08-10 | Univ Strathclyde | Modified amino acids and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK9192000A3 (en) | 1997-12-17 | 2001-03-12 | Merck & Co Inc | Integrin receptor antagonists |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6329372B1 (en) * | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| JP2009539815A (ja) * | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| WO2008093064A1 (en) * | 2007-01-29 | 2008-08-07 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS |
| GB201305668D0 (en) * | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| CN104817604B (zh) | 2015-03-16 | 2017-08-04 | 邦泰生物工程(深圳)有限公司 | 一种β‑烟酰胺单核苷酸的纯化方法 |
| JP2018514568A (ja) * | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
| KR20190026001A (ko) | 2016-07-05 | 2019-03-12 | 더 락커펠러 유니버시티 | 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질 |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| CN110167934B (zh) * | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| US11046685B2 (en) * | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| EP3843728B1 (en) | 2018-08-29 | 2025-04-30 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| CN115151566A (zh) | 2019-11-15 | 2022-10-04 | 普利安特治疗公司 | 用于活化整合素的组合物和方法 |
| KR20230049584A (ko) | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
| TW202235417A (zh) | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| US20230028658A1 (en) | 2021-04-30 | 2023-01-26 | Pliant Therapeutics, Inc. | Expanded dosage regimens for integrin inhibitors |
| US20240350494A1 (en) | 2021-09-03 | 2024-10-24 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
| JP2024539645A (ja) | 2021-10-14 | 2024-10-29 | プライアント・セラピューティクス・インコーポレイテッド | インテグリン阻害剤及び他の薬剤と組み合わせたその使用 |
-
2019
- 2019-06-26 TW TW108122460A patent/TWI841573B/zh active
- 2019-06-27 JO JOP/2020/0330A patent/JOP20200330A1/ar unknown
- 2019-06-27 WO PCT/US2019/039624 patent/WO2020006315A1/en not_active Ceased
- 2019-06-27 EP EP19826330.3A patent/EP3813818A4/en active Pending
- 2019-06-27 CR CR20210041A patent/CR20210041A/es unknown
- 2019-06-27 CN CN201980050125.6A patent/CN112689507B/zh active Active
- 2019-06-27 JP JP2020572976A patent/JP7425757B2/ja active Active
- 2019-06-27 SG SG11202013027RA patent/SG11202013027RA/en unknown
- 2019-06-27 IL IL279717A patent/IL279717B2/en unknown
- 2019-06-27 US US16/455,490 patent/US11396506B2/en active Active
- 2019-06-27 MX MX2020014086A patent/MX2020014086A/es unknown
- 2019-06-27 KR KR1020217002250A patent/KR20210043561A/ko not_active Withdrawn
- 2019-06-27 IL IL308960A patent/IL308960A/en unknown
- 2019-06-27 AU AU2019295769A patent/AU2019295769B2/en active Active
- 2019-06-27 BR BR112020026278-1A patent/BR112020026278A2/pt unknown
- 2019-06-27 CU CU2021000001A patent/CU24693B1/es unknown
- 2019-06-27 PE PE2020002165A patent/PE20210137A1/es unknown
- 2019-06-27 EA EA202190134A patent/EA202190134A1/ru unknown
- 2019-06-27 CA CA3104682A patent/CA3104682A1/en active Pending
-
2020
- 2020-12-23 CL CL2020003382A patent/CL2020003382A1/es unknown
- 2020-12-23 DO DO2020000255A patent/DOP2020000255A/es unknown
- 2020-12-23 PH PH12020552260A patent/PH12020552260A1/en unknown
- 2020-12-26 SA SA520420897A patent/SA520420897B1/ar unknown
-
2021
- 2021-01-12 ZA ZA2021/00211A patent/ZA202100211B/en unknown
- 2021-01-26 EC ECSENADI20215655A patent/ECSP21005655A/es unknown
-
2022
- 2022-02-23 US US17/679,002 patent/US11858931B2/en active Active
-
2023
- 2023-11-15 US US18/509,872 patent/US20240294520A1/en active Pending
-
2024
- 2024-01-19 JP JP2024006536A patent/JP2024055873A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020552260A1 (en) | Amino acid compounds with unbranched linkers and methods of use | |
| JOP20210056A1 (ar) | مركبات حمض أميني وطرق استخدامها | |
| EP4328230A3 (en) | Amino acid compounds and methods of use | |
| PH12020500529A1 (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
| JOP20200122A1 (ar) | مركبات مفيدة لتثبيط cdk7 | |
| MX2018005204A (es) | Inhibidores de isoindolina, azaisoindolina, dihidroindenona y dihidroazaindenona de cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2). | |
| TW201713633A (en) | Metallo-beta-lactamase inhibitors | |
| MX2014012454A (es) | Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria. | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| EP4249072A3 (en) | Crystalline forms of quinolone analogs and their salts | |
| PH12017501397B1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| MX2019010096A (es) | Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. | |
| MX2025007577A (es) | Inhibidores de la integrina alfa-v-beta-8 y sus usos | |
| MX2024007457A (es) | Formas cristalinas de n-(6-amino-5-metilpiridin-3-il)-2-(benzo[d]t iazol-5-il)-5- metilpiperidin-1-il)-2-oxoacetamida, composiciones farmacéuticas y métodos de uso de estas. | |
| SG11201810725WA (en) | Novel β-lactamase inhibitors | |
| MY191183A (en) | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | |
| IL276227A (en) | Crystal forms of the CXCR7 receptor antagonist (S4, S3)-1-cyclopropylmethyl-4-{[5-(4,2-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1 -pyrimidin-2-yl-cyclopropyl)-amide | |
| EA202092190A1 (ru) | Композиции и способы для лечения сильного запора | |
| MX2021008678A (es) | Compuesto de heteroarilo de anillo fusionado como inhibidor del receptor de tipo i de la activina (alk4) y/o el receptor de tipo i del factor beta de crecimiento transformante (tgf-beta) (alk5). | |
| MX2020002142A (es) | Un procedimiento para la preparacion de compuesto de triaminopirimidina e intermediarios del mismo. | |
| PH12022550774A1 (en) | Quinolone carboxylic acid derivatives | |
| EA202092110A1 (ru) | Аминокислотные соединения и способы применения | |
| MY207877A (en) | Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide |